Allison Bratzel
Stock Analyst at Piper Sandler
(3.89)
# 480
Out of 4,801 analysts
37
Total ratings
50%
Success rate
10.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $140 → $115 | $32.14 | +257.81% | 1 | Mar 17, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $4 → $6 | $1.77 | +238.98% | 1 | Mar 14, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $30 → $23 | $0.90 | +2,444.53% | 1 | Mar 11, 2025 | |
| ENGN enGene Holdings | Initiates: Overweight | $26 | $4.68 | +455.56% | 1 | Feb 18, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $620 → $725 | $550.00 | +31.82% | 13 | Jan 7, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $12 → $22 | $15.17 | +45.02% | 2 | Nov 14, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $23 | $17.04 | +34.98% | 2 | Nov 14, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $65 → $62 | $27.57 | +124.88% | 1 | Nov 14, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $28 → $42 | $26.04 | +61.29% | 3 | Oct 15, 2024 | |
| ROIV Roivant Sciences | Maintains: Overweight | $20 → $22 | $9.26 | +137.58% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.26 | +217.46% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $2.94 | +580.27% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $2.05 | +875.61% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $44 | $7.49 | +487.45% | 1 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $60.29 | +65.86% | 2 | Feb 8, 2023 |
Ultragenyx Pharmaceutical
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $32.14
Upside: +257.81%
Akebia Therapeutics
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $1.77
Upside: +238.98%
Inozyme Pharma
Mar 11, 2025
Maintains: Overweight
Price Target: $30 → $23
Current: $0.90
Upside: +2,444.53%
enGene Holdings
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $4.68
Upside: +455.56%
argenx SE
Jan 7, 2025
Maintains: Overweight
Price Target: $620 → $725
Current: $550.00
Upside: +31.82%
Travere Therapeutics
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $15.17
Upside: +45.02%
Rigel Pharmaceuticals
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $17.04
Upside: +34.98%
Ionis Pharmaceuticals
Nov 14, 2024
Maintains: Overweight
Price Target: $65 → $62
Current: $27.57
Upside: +124.88%
Scholar Rock Holding
Oct 15, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $26.04
Upside: +61.29%
Roivant Sciences
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $9.26
Upside: +137.58%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.26
Upside: +217.46%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $2.94
Upside: +580.27%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $2.05
Upside: +875.61%
Apr 17, 2023
Assumes: Overweight
Price Target: $44
Current: $7.49
Upside: +487.45%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $60.29
Upside: +65.86%